|
1
|
Rowinsky EK and Donehower RC: Paclitaxel
(Taxol). N Engl J Med. 332:1004–1014. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rowinsky EK, Cazenave LA and Donehower RC:
Taxol: a novel investigational antimicrotubule agent. J Natl Cancer
Inst. 82:1247–1259. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weiss RB, Donehower RC, Wiernik PH, Ohnuma
T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD and
Leyland-jones B: Hypersensitivity reactions from Taxol. J Clin
Oncol. 8:1263–1268. 1990.PubMed/NCBI
|
|
4
|
Singla AK, Garg A and Aggarwal D:
Paclitaxel and its formulations. Int J Pharm. 235:179–192. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Koudelka S and Turanek J: Liposomal
paclitaxel formulations. Journal Control Release. 163:322–334.
2012. View Article : Google Scholar
|
|
6
|
Jing X, Deng L, Gao B, Xiao L, Zhang Y, Ke
X, Lian J, Zhao Q, Ma L, Yao J, et al: A novel polyethylene glycol
mediated lipid nanoemulsion as drug delivery carrier for
paclitaxel. Nanomedicine. 10:371–380. 2014.
|
|
7
|
Zhang Z and Feng SS: The drug
encapsulation efficiency, in vitro drug release, cellular uptake
and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl
polyethylene glycol succinate nanoparticles. Biomaterials.
27:4025–4033. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huh KM, Min HS, Lee SC, Lee HJ, Kim S and
Park K: A new hydrotropic block copolymer micelle system for
aqueous solubilization of paclitaxel. J Control Release.
126:122–129. 2008. View Article : Google Scholar
|
|
9
|
Joshi MD and Muller RH: Lipid
nanoparticles for parenteral delivery of actives. Eur J Pharm
Biopharm. 71:161–172. 2009. View Article : Google Scholar
|
|
10
|
Lammers T, Kiessling F, Hennink WE and
Storm G: Drug targeting to tumors: principles, pitfalls and (pre-)
clinical progress. J Control Release. 161:175–187. 2012. View Article : Google Scholar
|
|
11
|
Constantinides PP, Tustian A and Kessler
DR: Tocol emulsions for drug solubilization and parenteral
delivery. Adv Drug Deliv Rev. 56:1243–1255. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Collins-gold L, Lyons R and Bartholow L:
Parenteral emulsions for drug delivery. Adv Drug Deliv Rev.
5:189–208. 1990. View Article : Google Scholar
|
|
13
|
Rodrigues DG, Covolan CC, Coradi ST,
Barboza R and Maranhão RC: Use of a cholesterol-rich emulsion that
binds to low-density lipoprotein receptors as a vehicle for
paclitaxel. J Pharm Pharmacol. 54:765–772. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rodrigues DG, Maria DA, Fernandes DC,
Valduga CJ, Couto RD, Ibañez OC and Maranhão RC: Improvement of
paclitaxel therapeutic index by derivatization and association to a
cholesterol-rich microemulsion: in vitro and in vivo studies.
Cancer Chemother Pharmacol. 55:565–576. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pires LA, Hegg R, Valduga CJ, Graziani SR,
Rodrigues DG and Maranhão RC: Use of cholesterol-rich nanoparticles
that bind to lipoprotein receptors as a vehicle to paclitaxel in
the treatment of breast cancer: pharmacokinetics, tumor uptake and
a pilot clinical study. Cancer Chemother Pharmacol. 63:281–287.
2009. View Article : Google Scholar
|
|
16
|
Teixeira RS, Valduga CJ, Benvenutti LA,
Schreier S and Maranhão RC: Delivery of daunorubicin to cancer
cells with decreased toxicity by association with a lipidic
nanoemulsion that binds to LDL receptors. J Pharm Pharmacol.
60:1287–1295. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vitols S, Peterson C, Larsson O, Holm P
and Aberg B: Elevated uptake of low density lipoproteins by human
lung cancer tissue in vivo. Cancer Res. 52:6244–6247.
1992.PubMed/NCBI
|
|
18
|
Maletínská L, Blakely EA, Bjornstad KA,
Deen DF, Knoff LJ and Forte TM: Human glioblastoma cell lines:
levels of low-density lipoprotein receptor and low-density
lipoprotein receptor-related protein. Cancer Res. 60:2300–2303.
2000.PubMed/NCBI
|
|
19
|
Stranzl A, Schmidt H, Winkler R and
Kostner GM: Low-density lipoprotein receptor mRNA in human breast
cancer cells: influence by PKC modulators. Breast Cancer Res Treat.
42:195–205. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xia X, Song X, Xu J, He J, Peng J, Zhang
X, Jin D, Abliz Z and Liu Y: Development of a validated
LC-APCI-MS/MS method to study the plasma and tumor distribution of
CHO-PTX intravenous lipid emulsion. J Pharm Biomed Anal.
117:532–543. 2016. View Article : Google Scholar
|
|
21
|
Stevens PJ, Sekido M and Lee RJ: A folate
receptor-targeted lipid nanoparticle formulation for a lipophilic
paclitaxel prodrug. Pharm Res. 21:2153–2157. 2004. View Article : Google Scholar
|
|
22
|
Xia XJ, Guo RF, Liu YL, Zhang PX, Zhou CP,
Jin DJ and Wang RY: Formulation, characterization and
hypersensitivity evaluation of an intravenous emulsion loaded with
a paclitaxel-cholesterol complex. Chem Pharm Bull (Tokyo).
59:321–326. 2011. View Article : Google Scholar
|
|
23
|
Torrisi R, Balduzzi A, Ghisini R, Rocca A,
Bottiglieri L, Giovanardi F, Veronesi P, Luini A, Orlando L, Viale
G, et al: Tailored preoperative treatment of locally advanced
triple negative (hormone receptor negative and HER2 negative)
breast cancer with epirubicin, cisplatin, and infusional
fluorouracil followed by weekly paclitaxel. Cancer Chemother
Pharmacol. 62:667–672. 2008. View Article : Google Scholar
|
|
24
|
Wang Q, Gong T, Sun X and Zhang Z:
Structural characterization of novel phospholipid lipid
nanoparticles for controlled drug delivery. Colloids Surf B
Biointerfaces. 84:406–412. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang R, Luo K, Yang J, Sima M, Sun Y,
Janát-Amsbury MM and Kopeček J: Synthesis and evaluation of a
backbone biodegradable multiblock HPMA copolymer nanocarrier for
the systemic delivery of paclitaxel. J Control Release. 166:66–74.
2013. View Article : Google Scholar :
|
|
26
|
Xiao K, Li Y, Lee JS, Gonik AM, Dong T,
Fung G, Sanchez E, Xing L, Cheng HR, Luo J, et al: 'OA02' peptide
facilitates the precise targeting of paclitaxel-loaded micellar
nanoparticles to ovarian cancer in vivo. Cancer Res. 72:2100–2110.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nagelkerke A, Bussink J, Sweep FC and Span
PN: Generation of multicellular tumor spheroids of breast cancer
cells: how to go three-dimensional. Anal Biochem. 437:17–19. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bonneau C, Rouzier R, Geyl C, Cortez A,
Castela M, Lis R, Daraï E and Touboul C: Predictive markers of
chemoresistance in advanced stages epithelial ovarian carcinoma.
Gynecol Oncol. 136:112–120. 2015. View Article : Google Scholar
|
|
29
|
Bernabeu E, Helguera G, Legaspi MJ,
Gonzalez L, Hocht C, Taira C and Chiappetta DA: Paclitaxel-loaded
PCL-TPGS nanoparticles: in vitro and in vivo performance compared
with Abraxane®. Colloids Surf B Biointerfaces.
113:43–50. 2014. View Article : Google Scholar
|
|
30
|
Mehta G, Hsiao AY, Ingram M, Luker GD and
Takayama S: Opportunities and challenges for use of tumor spheroids
as models to test drug delivery and efficacy. J Control Release.
164:192–204. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pampaloni F, Reynaud EG and Stelzer EH:
The third dimension bridges the gap between cell culture and live
tissue. Nat Rev Mol Cell Biol. 8:839–845. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Davies CD, Müller H, Hagen I, Gårseth M
and Hjelstuen MH: Comparison of extracellular matrix in human
osteosarcomas and melanomas growing as xenografts, multicellular
spheroids, and monolayer cultures. Anticancer Res. 17:4317–4326.
1997.
|
|
33
|
Kim SC, Kim DW, Shim YH, Bang JS, Oh HS,
Wan Kim S and Seo MH: In vivo evaluation of polymeric micellar
paclitaxel formulation: toxicity and efficacy. J Control Release.
72:191–202. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Desai N, Trieu V, Yao Z, Louie L, Ci S,
Yang A, Tao C, De T, Beals B, Dykes D, et al: Increased antitumor
activity, intratumor paclitaxel concentrations, and endothelial
cell transport of cremophor-free, albumin-bound paclitaxel,
ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res.
12:1317–1324. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Maranhão RC, Cesar TB, Pedroso-Mariani SR,
Hirata MH and Mesquita CH: Metabolic behavior in rats of a
nonprotein microemulsion resembling low-density lipoprotein.
Lipids. 28:691–696. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bauer KR, Brown M, Cress RD, Parise CA and
Caggiano V: Descriptive analysis of estrogen receptor
(ER)-negative, progesterone receptor (PR)-negative, and
HER2-negative invasive breast cancer, the so-called triple-negative
phenotype: a population-based study from the California Cancer
Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hudis CA and Gianni L: Triple-negative
breast cancer: an unmet medical need. Oncologist. 16(Suppl 1):
1–11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lei H, Hofferberth SC, Liu R, Colby A,
Tevis KM, Catalano P, Grinstaff MW and Colson YL: Paclitaxel-loaded
expansile nanoparticles enhance chemotherapeutic drug delivery in
mesothelioma 3-dimensional multicellular spheroids. J Thorac
Cardiovasc Surg. 149:1417–1425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xin H, Sha X, Jiang X, Zhang W, Chen L and
Fang X: Anti-glioblastoma efficacy and safety of paclitaxel-loading
Angiopep-conjugated dual targeting PEG-PCL nanoparticles.
Biomaterials. 33:8167–8176. 2012. View Article : Google Scholar : PubMed/NCBI
|
